All In Biotech

Drug Trial Radar · NCT04745689

Study of AZD2811 + Durvalumab in ES-SCLC

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

31

Actual

Start

Feb 23, 2021

Primary completion

Jun 18, 2022

Study completion Dec 1, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients with Extensive Stage Small-Cell Lung Cancer.

Conditions

  • Small-Cell Lung Cancer

Interventions

  • DurvalumabDrug

    IV infusions through induction phase. IV infusions through maintenance phase until PD or other discontinuation criteria.

  • AZD2811Drug

    IV infusions through maintenance phase until PD or other discontinuation criteria.

  • CarboplatinDrug

    IV infusions through induction phase if chosen by Investigator.

  • CisplatinDrug

    IV infusions through induction phase if chosen by Investigator.

  • EtoposideDrug

    IV infusions through induction phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maintenance Participants Alive and Progression Free (APF12) Per RECIST 1.1 [Efficacy]Time frame: Up to 12 months

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Olsztyn, Poland

  • Research Site

    Poznan, Poland

  • Research Site

    Cheongju-si, South Korea

  • Research Site

    Jinju, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seville, Spain

  • Research Site

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.